Indigo-Clean is offering an upper-air disinfection claim: that it kills 90 percent of SARS-CoV-2 in just 2 hours at normal illuminance levels.
Indigo-Clean has been validated by both the Icahn School of Medicine at Mount Sinai in New York City and the University of Tennessee to safely kill SARS-CoV-2 without damage to eyes, skin or materials.
The system often goes unnoticed in the perimeter of surgical suites and other healthcare spaces. Decades-old ultraviolet lights, originally installed to kill bacteria that causes tuberculosis, were largely discontinued, due to safety concerns for room occupants, as well as maintenance issues, according to an Indigo-Clean press release.
Indigo-Clean is now offering a welcome disinfection alternative: 405nm visible light.
Today, UV is primarily used in hospitals for surface disinfection, via portable devices that must operate while the room is unoccupied. With the onset of the pandemic, a number of lighting manufacturers began promoting UV for upper air disinfection in occupied spaces, while attempting to downplay unresolved safety and maintenance concerns.
To be effective, UV require direct sightlines, which can be a significant challenge in ORs filled with beds and equipment.
According to the United States Food and Drug Administration (FDA), improperly deployed UV lighting can cause a number of health issues, including skin and eye burns. The 405nm wavelength used by Indigo-Clean is considered 'risk exempt', per the International Electrotechnical Commission (IEC) Standard 62471, which evaluates the photobiological safety of lamps. The standard assigns specific risk levels to all forms of UV light, which means under certain circumstances, they can cause skin and eye irritation and/or damage.
Legrand release
